Overview

* Teleflex ( TFX ) Q3 GAAP revenue up 19.4% yr/yr, adjusted revenue up 16.8%

* Adjusted EPS for Q3 rises to $3.67, despite GAAP EPS loss

* Company narrows full-year revenue growth guidance, lowers EPS outlook

Outlook

* Teleflex ( TFX ) narrows 2025 GAAP revenue growth outlook to 9.10% to 9.60%

* Company lowers 2025 adjusted constant currency revenue growth to 6.90% to 7.40%

* Teleflex ( TFX ) decreases 2025 GAAP EPS outlook to $(4.42) to $(4.22)

* Progress in separating into RemainCo and NewCo, with potential sale of NewCo as a focus

Result Drivers

* VASCULAR INTERVENTION - Revenue from acquired Vascular Intervention business exceeded guidance, aiding overall revenue growth

* INTRA-AORTIC BALLOON PUMPS - Lower-than-expected order rates impacted revenue, particularly in the U.S.

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $3.67

Adjusted

EPS

continui

ng

operatio

ns

Q3 EPS -$9.24

continui

ng

operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 12 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Teleflex Inc ( TFX ) is $135.00, about 7.6% above its November 5 closing price of $124.75

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)